Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (111-120 of 201) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2007
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group StudyPeter G Rose, Shamshad Ali, Edwin Watkins, et al.
Anti-Cancer Drugs|July 23, 2020
Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicinPeter G Rose, Frances Fu, Laura M Chambers, et al.
Gynecologic Oncology|July 27, 2015
Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancerHaider Mahdi, Allison Gockley, Katherine Esselen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of ChemoradiotherapyPeter G Rose, James Java, Charles W Whitney, et al.
Gynecologic Oncology|August 6, 2014
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyLinda R Duska, John A Blessing, Jacob Rotmensch, et al.
Journal of Gynecology Obstetrics and Human Reproduction|June 27, 2020
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancerAnthony B Costales, Laura Chambers, Anna Chichura, et al.
Gynecologic Oncology|May 1, 2024
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resectionJulia Chalif, Laura M Chambers, Meng Yao, et al.
Gynecologic Oncology|March 11, 2022
Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancerJulia Chalif, Meng Yao, Morgan Gruner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 11, 2026
Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinomaPeter G Rose, Sujata Patil, Meng Yao, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 6, 2023
Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancerErika J Lampert, Peter G Rose, Meng Yao, et al.
Pageof 21

Showing results (111-120 of 201) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2007
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group StudyPeter G Rose, Shamshad Ali, Edwin Watkins, et al.
Anti-Cancer Drugs|July 23, 2020
Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicinPeter G Rose, Frances Fu, Laura M Chambers, et al.
Gynecologic Oncology|July 27, 2015
Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancerHaider Mahdi, Allison Gockley, Katherine Esselen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of ChemoradiotherapyPeter G Rose, James Java, Charles W Whitney, et al.
Gynecologic Oncology|August 6, 2014
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyLinda R Duska, John A Blessing, Jacob Rotmensch, et al.
Journal of Gynecology Obstetrics and Human Reproduction|June 27, 2020
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancerAnthony B Costales, Laura Chambers, Anna Chichura, et al.
Gynecologic Oncology|May 1, 2024
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resectionJulia Chalif, Laura M Chambers, Meng Yao, et al.
Gynecologic Oncology|March 11, 2022
Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancerJulia Chalif, Meng Yao, Morgan Gruner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 11, 2026
Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinomaPeter G Rose, Sujata Patil, Meng Yao, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 6, 2023
Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancerErika J Lampert, Peter G Rose, Meng Yao, et al.
Pageof 21